BlackRock Investment Management’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2016
Q4
$55.7M Buy
853,473
+54,437
+7% +$3.53M 0.06% 283
2016
Q3
$56.5M Buy
799,036
+67,087
+9% +$4.89M 0.07% 271
2016
Q2
$54.1M Buy
731,949
+84,710
+13% +$5.85M 0.07% 278
2016
Q1
$42M Buy
647,239
+176,110
+37% +$12M 0.05% 324
2015
Q4
$36.3M Sell
471,129
-47,447
-9% -$3.77M 0.05% 355
2015
Q3
$42.7M Buy
518,576
+19,077
+4% +$1.7M 0.06% 307
2015
Q2
$44M Buy
499,499
+53,569
+12% +$4.91M 0.05% 318
2015
Q1
$39.4M Sell
445,930
-4,231
-0.9% -$375K 0.05% 343
2014
Q4
$37.4M Buy
450,161
+35,241
+8% +$2.92M 0.05% 351
2014
Q3
$35M Buy
414,920
+10,242
+3% +$829K 0.05% 346
2014
Q2
$32.8M Sell
404,678
-31,726
-7% -$2.5M 0.04% 380
2014
Q1
$33.2M Buy
436,404
+51,938
+14% +$3.78M 0.05% 349
2013
Q4
$27.7M Buy
384,466
+13,226
+4% +$919K 0.04% 385
2013
Q3
$25.5M Buy
371,240
+64,461
+21% +$4.26M 0.04% 389
2013
Q2
$19.4M Buy
+306,779
New +$20M 0.03% 447

Other funds holding NVS

BlackRock Investment Management's NVS Position: Q4 2016 in Review

BlackRock Investment Management increased its Novartis (NVS) stake by 6.8% in Q4 2016, buying an estimated $3.53M and bringing the position to 853,473 shares worth $55.7M. The position accounts for 0.06% of the portfolio, ranked #283.

BlackRock Investment Management first reported a position in NVS in Q2 2013 and has held it in 15 quarters since. The position peaked at $56.5M in Q3 2016. 904 funds tracked by Wall St. Rank hold NVS as of Q4 2016.

  • BlackRock Investment Management held 853,473 shares of Novartis worth $55.7M as of Q4 2016.
  • BlackRock Investment Management bought 54,437 Novartis shares in Q4 2016, an estimated $3.53M.
  • Novartis made up 0.06% of BlackRock Investment Management's portfolio in Q4 2016, its #283 holding.
  • BlackRock Investment Management first reported a position in Novartis in Q2 2013 and has held it in 15 quarters since.
  • BlackRock Investment Management's Novartis position peaked at $56.5M in Q3 2016.
  • 904 funds tracked by Wall St. Rank held Novartis as of Q4 2016.

Based on BlackRock Investment Management's 13F filing for Q4 2016, filed 10 Feb 2017.